Singapore eDevelopment's Global BioLife confirms LB2 efficacy against Ebola
Mar 01, 2018 14:00 HKT |  |
|
Holista Group Company signs US$6M MOU to supply Low-GI Noodle Mix to Wing's of Canada
Feb 14, 2018 17:00 HKT |  |
|
Proteomics International announces Strategic Alliance and Investment in CPR Pharma Services
Feb 12, 2018 06:00 HKT |  |
|
Sanofi Delivers 2017 Business EPS in line with Guidance
Feb 07, 2018 15:00 HKT |  |
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting
Jan 22, 2018 15:00 HKT |  |
|
Sanofi to Acquire Bioverativ for $11.6 Billion
Jan 22, 2018 14:00 HKT | |
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers
Jan 11, 2018 15:00 HKT | |
|
Nanobiotix: 2017 review and 2018 expected milestones
Dec 26, 2017 15:50 HKT | |
|
FDA approves Nanobiotix's first Immuno-Oncology trial
Dec 26, 2017 15:15 HKT | |
|
Singapore Institutes Collaborate with Samsung Medical Center to Improve Treatment of Liver Cancer
Dec 14, 2017 10:00 HKT |  |
|
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting
Nov 13, 2017 15:00 HKT | |
|
Nanobiotix provides update on the global development of its lead product NBTXR3
Nov 10, 2017 08:30 HKT | |
|
Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
Nov 01, 2017 18:00 HKT | |
|
Singapore eDevelopment's Global BioLife develops Low-GI Modified Sugar
Oct 24, 2017 18:00 HKT | |
|
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma
Oct 23, 2017 14:00 HKT | |
|
ASX-Listed Holista and Holista Foods Inc. (USA) Develop Breakthrough Noodle Formula with Low-Glycemic Score of 38
Oct 19, 2017 16:00 HKT | |
|
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China
Oct 17, 2017 14:30 HKT |  |
|
Sanofi: Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent(R) (alirocumab)
Oct 06, 2017 08:00 HKT | |
|
Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.
Sep 29, 2017 08:00 HKT | |
|
Nanobiotix half year results for the six months ended 30 June 2017
Sep 01, 2017 01:30 HKT | |
|